Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook.

Matchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

Teva Pharmaceutical Industries announced FDA approval of Weltruza (olanzapine) extended-release injectable suspension, the first once-monthly subcutaneous formulation for treating schizophrenia in adults. The drug will launch in the U.S. in coming weeks with three dosage strengths and requires no loading doses or post-injection monitoring. This approval expands Teva's schizophrenia portfolio alongside its existing Uzedy product, which generated $140 million in sales in the first half of 2026.

Retension Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular diseases, priced its IPO at $12 per share, raising $45 million gross proceeds. The company plans to use the funds to complete Phase 2b trials and prepare for Phase 3 trials of its lead candidate RTN-001. Trading on Nasdaq under ticker RTSN is expected to begin October 9, 2026.

Sanofi announced the availability of its Q3 2026 results aide-mémoire on October 6, 2026, with full results to be published on October 30, 2026. The company also announced expansions of strategic partnerships with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines.

Sanofi announced the publication of its Q3 2026 aide-mémoire on October 6, 2026, with full quarterly results to follow on October 30, 2026. The company also announced expansions of strategic alliances with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines partnerships.

Sanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030.

GSK and Sanofi, two major European pharmaceutical companies, are compared across growth drivers, pipelines, and valuations. GSK shows strong specialty medicines growth (14% in H1 2026) with expanding oncology and HIV franchises, while Sanofi benefits from blockbuster Dupixent sales (up 28.6%) and stronger near-term earnings growth. Despite both holding Hold ratings, Sanofi appears better positioned due to superior earnings growth outlook, favorable valuation metrics, and positive estimate revisions, though it faces vaccine sales headwinds and heavy Dupixent reliance.

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

Regeneron Pharmaceuticals' stock has declined from over $1,000 to below $800 over the past two years, primarily due to challenges with its Eylea product facing biosimilar competition. However, the company shows strong fundamentals with 17% revenue growth driven by Dupixent, successful mitigation of Eylea losses through its HD formulation, and promising pipeline candidates including the weight-loss drug olatorepatide. The analyst views the stock as attractive at current levels given its long-term growth prospects and shareholder return programs.

Recludix Pharma, a clinical-stage biotech company focused on inflammatory disease treatments, announced that its CEO and head of R&D will present at the Oppenheimer Private Life Sciences Company Showcase on September 29, 2026. The company is developing STAT6 and BTK inhibitors in partnership with Sanofi, with a Phase 1 study underway for REX-8756 targeting diseases like atopic dermatitis and asthma.